Opinion
MIS for cervical cancer: Is it not for anyone or not for everyone?
Dr. Rossi proposes a hypothesis for the results that suggests not all surgeons need abandon MIS for cervical cancer.
Opinion
When is hysterectomy appropriate for cervical dysplasia?
In this month's Gynecologic Oncology Consult, Dr. Emma C. Rossi discusses critical counseling for cervical dysplasia patients offered hysterectomy...
Opinion
A new way to classify endometrial cancer
If researchers can better define patients’ endometrial cancer at the time of their biopsy, important clinical decisions might be able to be...
Opinion
What is HIPEC?
In this month’s column, Dr. Emma Rossi examines the use of hyperthermic intraperitoneal chemotherapy for ovarian cancer treatment.
Opinion
Same-day discharge for hysterectomy
Dr. Emma Rossi reviews how to best predict who is a good candidate for same-day discharge.
Opinion
Telling her she has cancer: A patient-centered approach to breaking bad news
The SPIKES approach is a helpful tool for applying consistent principles to the needs of individual patients.
Opinion
Complex atypical hyperplasia: When is it appropriate to refer?
An accurate preoperative or intraoperative diagnosis can help a patient avoid a second surgery.
Opinion
Strategies to evaluate postmenopausal bleeding
Pros and cons of blind and targeted sampling.
Opinion
Approaching intraoperative bowel injury
Familiarity with bowel anatomy is important in order to accurately diagnose the extent of injury and determine the optimal repair technique.
Opinion
Low malignant potential tumors of the ovary: A review
Surgeons who manage these tumors can safely consider fertility sparing procedures but should be prepared to completely resect all disease.
Opinion
Optimizing HPV vaccination
Moving to a two-dose vaccine schedule in the under-15 age group will help improve vaccination completion rates but more needs to be done.
Opinion
Understanding the human papillomavirus
In her column, Dr. Emma Rossi reviews the fundamentals of HPV biology, epidemiology, and carcinogenesis.
Opinion
PARP inhibitors: New developments in ovarian cancer treatment
Maturing data from ongoing trials will likely expand the opportunity to use PARP inhibitors for the treatment of ovarian cancer.